Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 106

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 106
---
, he has built the Company from scratch and, during that time, he led strategy, built a highly experienced team
of leaders, spearheaded the acquisition and development of the Company’s core AI technology and drug assets, secured the first
revenue, and raised approximately $2 million in financing prior to the Company’s IPO in February 2023. In February of 2020, he
formed Bullfrog AI Holdings, Inc., and Bullfrog AI Inc. became a wholly owned subsidiary designated as the holder of core intellectual
property. Vin is a serial entrepreneur and experienced executive with 25 years of experience in the life sciences and biotechnology industries.
He has extensive start-up experience having founded and built several pioneering investor-backed companies including Bullfrog AI, which
uses AI/ML to enable drug development, Next Healthcare Inc., a personalized diagnostics and adult cell banking service, and MaxCyte Inc.
(NASDAQ: MXCT), a cell therapy company. He was also an executive at GlobalStem Inc. and ThermoFisher Scientific, leading their global
cell therapy services business. Vin has a B.S. in Electrical Engineering from Rutgers University, an M.S. in Biomedical Engineering from
Rensselaer Polytechnic Institute, and an M.B.A. from Johns Hopkins University. We believe that Mr. Singh is qualified to serve as a member
of our board of directors due to the perspective and experience that he brings as our founder and Chief Executive Officer, his extensive
experience in the science and biotechnology industries and in the management of startup companies.

Josh
Blacher has been the Chief Financial Officer of Bullfrog AI Holdings, Inc. since December 2024. Mr. Blacher has served as an employee
of Danforth Advisors since September 2022, where he has worked as a chief financial officer in a consulting capacity for a number of
life sciences companies as well as Managing Partner of Columbus Circle Capital LLC since August 2019. In his capacity as a consultant
of Danforth, he has served as Chief Financial Officer of Predictive Oncology since September 2023 as well as Rampart Bioscience and Excision
Bio Therapeutics, among others. During his tenure at Columbus Circle Capital, Mr. Blacher has served as chief financial officer at several
public and private companies. Prior to his tenure at Columbus Circle Capital, Mr. Blacher served as Chief Business Officer at Inmed Pharmaceuticals
(Nasdaq: INM) from April 2018 to August